Iomai Receives FDA Clearance For Study Comparing Novel Flu Vaccine Patch To Traditional Injectable Vaccine

... Iomai Corporation (Nasdaq: IOMI) announced today that it has received clearance from the U.S. Food and Drug Administration to launch a head-to-head trial comparing its needle-free, patch-based influenza vaccine with the traditional vaccine,delivered via intramuscular injection. The study will enroll up to 300patients and begin later this month. [click link for full article] ...